Literature DB >> 22119103

Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis.

Tanaz A Kermani1, Jean Schmidt, Cynthia S Crowson, Steven R Ytterberg, Gene G Hunder, Eric L Matteson, Kenneth J Warrington.   

Abstract

OBJECTIVES: To evaluate the utility of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) for the diagnosis of giant cell arteritis (GCA) and to determine the frequency of normal ESR and CRP at diagnosis of GCA.
METHODS: All patients undergoing temporal artery biopsy (TAB) between 2000 and 2008 were identified. Only subjects with both ESR and CRP at the time of TAB were included. The medical records of all patients were reviewed.
RESULTS: We included 764 patients (65% women), mean age 72.7 (±9.27) years, who underwent TAB. Biopsy was consistent with GCA in 177 patients (23%). Elevated CRP and elevated ESR provided a sensitivity of 86.9% and 84.1%, respectively, for a positive TAB. The odds ratio of a concordantly elevated ESR and CRP for positive TAB was 3.06 (95% CI 2.03, 4.62), whereas the odds ratio for concordantly normal ESR and CRP was 0.49 (95% CI 0.29, 0.83). Seven patients (4%) with a positive TAB for GCA had a normal ESR and CRP at diagnosis. Compared with GCA patients with elevated markers of inflammation, a greater proportion of these patients had polymyalgia rheumatica symptoms (P = 0.008), whereas constitutional symptoms, anemia and thrombocytosis, were observed less often (P < 0.05).
CONCLUSIONS: CRP is a more sensitive marker than ESR for a positive TAB that is diagnostic of GCA. There may be clinical utility in obtaining both tests in the evaluation of patients with suspected GCA. A small proportion of patients with GCA may have normal inflammatory markers at diagnosis.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22119103      PMCID: PMC3307891          DOI: 10.1016/j.semarthrit.2011.10.005

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  15 in total

1.  Giant cell arteritis with an erythrocyte sedimentation rate lower than 50.

Authors:  V M Martínez-Taboada; R Blanco; J Armona; E Uriarte; M Figueroa; M A Gonzalez-Gay; V Rodriguez-Valverde
Journal:  Clin Rheumatol       Date:  2000       Impact factor: 2.980

2.  The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis.

Authors:  G G Hunder; D A Bloch; B A Michel; M B Stevens; W P Arend; L H Calabrese; S M Edworthy; A S Fauci; R Y Leavitt; J T Lie
Journal:  Arthritis Rheum       Date:  1990-08

Review 3.  Does this patient have temporal arteritis?

Authors:  Gerald W Smetana; Robert H Shmerling
Journal:  JAMA       Date:  2002-01-02       Impact factor: 56.272

4.  Giant cell arteritis: validity and reliability of various diagnostic criteria.

Authors:  S S Hayreh; P A Podhajsky; R Raman; B Zimmerman
Journal:  Am J Ophthalmol       Date:  1997-03       Impact factor: 5.258

5.  Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up.

Authors:  V Kyle; T E Cawston; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1989-08       Impact factor: 19.103

6.  Giant cell arteritis: laboratory predictors of a positive temporal artery biopsy.

Authors:  Matthew D Walvick; Michael P Walvick
Journal:  Ophthalmology       Date:  2011-01-12       Impact factor: 12.079

7.  Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis.

Authors:  M C Cid; C Font; J Oristrell; A de la Sierra; B Coll-Vinent; A López-Soto; J Vilaseca; A Urbano-Márquez; J M Grau
Journal:  Arthritis Rheum       Date:  1998-01

8.  A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis.

Authors:  G Myklebust; J T Gran
Journal:  Br J Rheumatol       Date:  1996-11

9.  Alpha 1-antichymotrypsin, C-reactive protein and erythrocyte sedimentation rate in polymyalgia rheumatica and giant cell arteritis.

Authors:  G D Pountain; J Calvin; B L Hazleman
Journal:  Br J Rheumatol       Date:  1994-06

10.  The ESR in the diagnosis and management of the polymyalgia rheumatica/giant cell arteritis syndrome.

Authors:  M E Ellis; S Ralston
Journal:  Ann Rheum Dis       Date:  1983-04       Impact factor: 19.103

View more
  68 in total

Review 1.  Neuro-Ophthalmological Emergencies.

Authors:  João Lemos; Eric Eggenberger
Journal:  Neurohospitalist       Date:  2015-10

2.  Temporal artery biopsy in giant cell arteritis--reply.

Authors:  Lindsey B De Lott; James F Burke; Jonathan D Trobe
Journal:  JAMA Ophthalmol       Date:  2015-10       Impact factor: 7.389

3.  Giant cell arteritis with normal ESR and/or CRP is rare, but not unique!

Authors:  A Grzybowski; A Justynska
Journal:  Eye (Lond)       Date:  2013-09-20       Impact factor: 3.775

4.  Response to Grzybowski and Justynska.

Authors:  S L Levy; A D Bull; A R Nestel
Journal:  Eye (Lond)       Date:  2013-09-20       Impact factor: 3.775

Review 5.  [Management of polymyalgia rheumatica and large vessel vasculitis].

Authors:  B Hellmich
Journal:  Internist (Berl)       Date:  2016-11       Impact factor: 0.743

6.  Unusual optic disc infarction in a case of arteritic anterior ischaemic optic neuropathy (AAION).

Authors:  D K Lim; S Shen; I A Jejah; J F Cullen
Journal:  Singapore Med J       Date:  2015-03       Impact factor: 1.858

7.  Comment on: How common is inflammatory marker-negative disease in giant cell arteritis?

Authors:  T A Kermani; K J Warrington
Journal:  Eye (Lond)       Date:  2013-03-08       Impact factor: 3.775

8.  Response to comment on: how common is inflammatory marker-negative disease in giant cell arteritis?

Authors:  S L Levy; A D Bull; A R Nestel
Journal:  Eye (Lond)       Date:  2013-03-08       Impact factor: 3.775

9.  Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016.

Authors:  Antoine G Sreih; Fatma Alibaz-Oner; Tanaz A Kermani; Sibel Z Aydin; Peter F Cronholm; Trocon Davis; Ebony Easley; Ahmet Gul; Alfred Mahr; Carol A McAlear; Nataliya Milman; Joanna C Robson; Gunnar Tomasson; Haner Direskeneli; Peter A Merkel
Journal:  J Rheumatol       Date:  2017-09-01       Impact factor: 4.666

10.  A hidden giant: Wallenberg syndrome and aortal wall thickening as an atypical presentation of a giant cell arteritis.

Authors:  Katharina Luisa Stengl; Ralph Buchert; Hans Bauknecht; Jan Sobesky
Journal:  BMJ Case Rep       Date:  2013-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.